FDA Brief

Warning letters Drugs

FDA warning letter to

Kingdom Harvest

High riskIssued May 4, 2022Posted May 4, 2022Center for Drug Evaluation and Research | CDER

Kingdom Harvest marketed CBD and Delta-8 THC products with unapproved drug claims and unsafe food and animal drug uses.

What happened

FDA reviewed Kingdom Harvest's website from October 2021 through April 2022 and its Facebook and Instagram pages. FDA found the company took orders for CBD and Delta-8 THC products for humans and animals and made claims that they treat or prevent conditions such as COVID-19, opioid withdrawal, pain, anxiety, epilepsy, and cancer. FDA also found CBD added to conventional foods and CBD products marketed for food-producing animals.

What FDA found

  1. CBD and Delta-8 THC products for humans are unapproved new drugs because they are marketed to treat or prevent disease without an FDA-approved application.

    FD&C Act §§505(a), 301(d), 21 U.S.C. 355(a), 331(d)
  2. The human CBD and Delta-8 THC drugs are misbranded because their labeling lacks adequate directions for use.

    FD&C Act §502(f)(1), 21 U.S.C. 352(f)(1)
  3. CBD added to honey, coffee, and tea is an unsafe food additive, so those foods are adulterated.

    FD&C Act §402(a)(2)(C)(i), 21 U.S.C. 342(a)(2)(C)(i)
  4. CBD pet and livestock products are unapproved new animal drugs that are unsafe and adulterated.

    FD&C Act §§512(a), 501(a)(5), 21 U.S.C. 360b(a), 351(a)(5)
  5. The company's CBD products cannot be dietary supplements because CBD is excluded from the dietary supplement definition.

    FD&C Act §201(ff)(3)(B)(i)-(ii), 21 U.S.C. 321(ff)(3)(B)(i)-(ii)
  6. Adding CBD to food and introducing it into interstate commerce is a prohibited act.

    FD&C Act §301(ll), 21 U.S.C. 331(ll)

What FDA wants

FDA tells the company to take immediate action to cease sale of unapproved CBD products for food-producing animals and to correct the illegal marketing of its CBD and Delta-8 THC products.

Who should pay attention

  • retailers and online marketplaces selling CBD or Delta-8 products
  • brands using CBD in foods or pet and livestock products
  • contract manufacturers and labs testing hemp-derived products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk